INTRODUCTION
A lthough most infantile hemangiomas regress on their own, facial lesions cause significant distress to parents and are associated with a risk of scarring, disfigurement, and airway obstruction, apart from syndromic associations. Management of these lesions has changed considerably in the last few years with the advent of topical timolol preparations. [1] [2] [3] We describe the case of an infant who had a superficial perioral and segment three hemangioma with ulceration, who responded dramatically to topical timolol 0.5% ophthalmic solution. for 2 months. She was advised to watch for side effects including sleep disturbances, poor feeding, irritability or lethargy, and review when any appeared. Marked improvement was noted at 2 months [ Figure 2 ]. There were no side effects.
DISCUSSION
Infantile hemangiomas usually regress spontaneously and do not need treatment as "active nonintervention" is considered the gold standard. Treatment is needed in those with ulceration, disfigurement or impairment of function or vital structures. [1] Nothing can reliably predict the timing and extent of involution of the infantile hemangiomas, hence enlarging lesions on visible areas are significantly distressing to parents. However, early treatment has shown to suppress growth. [2] Our patient had segment three involvement, so he was at risk for airway obstruction, coarctation of the aorta and posterior fossa anomalies, hemangioma, arterial anomalies, cardiac anomalies, eye anomalies, sternal defects syndrome. [3] He also had an ulcerated perioral lesion, which put him at high risk for functional compromise and disfigurement. Lower lip hemangioma is a common site for ulceration owing to friction and moisture; finally leading to scarring and poor oral intake. Bleeding, seen in 40% of ulcerations, wasn't seen in our patient. Apart from wound care, infection and pain control, ulceration warrants therapy in the form of laser treatment, excision or propranolol. In a recent report from India, topical timolol has been proven to be effective for an ulcerated infantile hemangioma over the buttock. [4] According to the growth phase of the lesions, they are classified as nascent, early and late proliferative, plateau, involuting, and abortive stages. As 80% of their maximum size is mostly reached by 5 months, [5] our patient was most probably in the plateau stage.
Timolol solution 0.5% has been found to be useful in small superficial hemangiomas and in facial hemangiomas presenting early under close supervision and switching to oral propranolol in the event that a high-risk feature develops. [1] The advantages of timolol solution are its cost, availability, ease of administration, and minimal risk of systemic side effects. [2] Although the recent Cochrane review did not include topical timolol and concluded that first line therapy for life-or function-threatening hemangiomas is still corticosteroid, [6] the standard of care has shifted completely since to β-blockers. [3] We followed the recommendations on use of timolol including the limitation of dosage to one to two drops per application with an awareness of manifestations of systemic absorption including irritability, lethargy, and poor feeding. [7] In a retrospective study involving 73 patients with superficial hemangiomas without ulceration, only one had a side effect, namely, sleep disturbance. [2] In a series of 11 patients treated with timolol 0.5% gel manufactured from ophthalmic solution, the gel was occluded using Finn Chambers and used once a day. Systemic absorption is highly unlikely from transdermal absorption, even when compared to ophthalmic administration, [8] however, our patient was administered the drops over the tongue also without any complications. Dosing of topical timolol without occlusion has varied from twice daily [2, 9] to even 5 times a day. [10] This is the first report of topical timolol use in a high risk site, over an ulcerated facial lesion and on the tongue, to the best of our knowledge, without any complications and with remarkable improvement at 2 months. We suggest that timolol ophthalmic solution may be an option for such lesions in a resource-poor setting under close monitoring.
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